MANKIND - Mankind Pharma Limited Share Price

In the earnings call for Q4 & FY26 held on May 20, 2026, Mankind Pharma's management provided a positive outlook for FY27, emphasizing expected growth across various business segments. Rajeev Juneja, Vice Chairman and Managing Director, stated that overall top-line growth for FY27 would exceed last year's double-digit growth, with a projected adjusted EBITDA margin in the range of 25.5% to 26.5%.

Key forward-looking points included:

1. Revenue Performance: Q4 FY26 showcased an 11.8% increase in revenue year-on-year to INR 3,443 crores, while FY26 saw a 17% revenue growth to INR 14,278 crores. The management anticipates continued momentum in both domestic and international markets.

2. Specialty Offerings: The company's strategic focus is shifting towards specialty chronic therapies and R&D-led innovations. The acquisition of the Rivotril brand is expected to strengthen their specialty portfolio.

3. Domestic Business Growth: Domestic revenue grew by 14.4% yearly in FY26, driven by strong performance in acute and chronic therapies, with expectations for recovery in acute business post-disruptions faced previously.

4. International Expansion: The international business registered a 35% increase in revenue for FY26, with optimistic projections for sustained higher growth as they expand in semi-regulated markets.

5. Cost Management: Management indicated a gross margin improvement due to better sales mix and operational efficiency. They emphasized ongoing initiatives to manage employee costs while ensuring growth potentials are maintained.

6. R&D Investments: R&D expenditures are projected at 2.8% of sales, aligning with long-term growth strategies and pipeline development.

The management expressed confidence that FY27 would be a significantly improved year for all business segments, driven by disciplined execution and strategic initiatives.

Question 1: Kunal Dhamesha: "Sir, where do you put progress on those aspects now? Do you think that the entire disruption is behind us? Are we back to business as usual for our domestic business?"

Answer: Kunal, we've made the necessary corrections and are now on a recovery path. Our overall performance in Q4 and FY26 reflects this improvement. While disruptions impacted our acute sector, our chronic business remained stable. We are positioned for better growth in FY27, as our teams are now appropriately placed and functioning in a favorable environment.

Question 2: Kunal Dhamesha: "Sir, could you provide an outlook for top-line growth for FY27 as well as the profitability outlook?"

Answer: We anticipate double-digit top-line growth for FY27, exceeding last year's performance. For EBITDA, we expect margins in the range of 25.5% to 26.5%, which should also see an improvement compared to FY26.

Question 3: Kunal Dhamesha: "Where are we on the GLP-1 journey, and what is our positioning?"

Answer: Kunal, we launched our GLP-1 product about a month ago, targeting endocrinologists primarily. We believe GLP-1 offers a long-term opportunity, and our strategy involves not compromising on profitability while also considering adjacent therapies to strengthen our growth trajectory.

Question 4: Tushar Manudhane: "What's happening on the raw material cost side given geopolitical issues?"

Answer: Tushar, we acknowledge some disruption in raw material costs due to ongoing geopolitical situations. We've implemented precautions to manage these impacts, and we aim to maintain our margin expectations despite these challenges.

Question 5: Tushar Manudhane: "Could you highlight initiatives to revive consumer health growth?"

Answer: We've focused on fundamentals; our goal is double-digit growth in the consumer division backed by line extensions of existing brands. We also see potential growth from e-commerce channels, which are expanding rapidly, contributing to our overall strategy.

Question 6: Harith: "Could you elaborate on chronic therapy performance related to Q4 softness? Are there pressures?"

Answer: There are no pressures on chronic therapies; our long-term growth trajectory remains strong despite short-term fluctuations. Chronic segments like anti-diabetes and cardiac care are underpenetrated, and we are confident in sustainable growth moving forward.

Question 7: Sidharth: "Has there been a significant decline in employee expenses, and is there any manpower rationalization?"

Answer: The employee costs dropped due to our incentive-related adjustments and a waiver in director fees. On an annual basis, employee costs increased around 10%, factoring in the BSV acquisition. We expect this to stabilize, keeping costs around 22% of overall revenue.

Question 8: Bharat Shah: "Is BSV delivering expected strategic benefits post-acquisition?"

Answer: Absolutely. Although it's too early to make definitive claims, we believe BSV's integration is on track and contributing positively to our growth. We expect to see stronger results as the integration matures and processes get streamlined.

Question 9: Alka Katiyar: "Can you highlight the debt repayment plan moving forward?"

Answer: We are on track with our debt repayment plan. The latest payment was INR1,250 crores, with another due in October. We expect to reduce net debt to adjusted EBITDA ratio to 0.5x by FY27 while managing our ongoing acquisition-related debts effectively.

Question 10: Bharat Shah: "What is the expected effective tax rate for FY27?"

Answer: For FY27, our expected effective tax rate will be in the range of 25% to 26%. This increase is due to the expiration of tax exemptions previously enjoyed in Sikkim, as seen in FY26.